ELTX

Elicio Therapeutics (ELTX)

Elicio Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ELTX

1 2 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/28	22:00	GlobeNewswire Inc.	Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/06/28	05:05	GlobeNewswire Inc.	Elicio Therapeutics Announces Proposed Public Offering	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/06/28	05:01	GlobeNewswire Inc.	Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/06/18	21:30	GlobeNewswire Inc.	Elicio Therapeutics Reports Inducement Grants	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/06/12	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/06/12	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/06/04	06:24	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/06/04	05:41	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/05/24	06:30	GlobeNewswire Inc.	Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/05/16	05:34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/05/16	05:30	GlobeNewswire Inc.	Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/04/25	21:30	GlobeNewswire Inc.	Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/04/06	05:30	GlobeNewswire Inc.	Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/03/29	21:30	GlobeNewswire Inc.	Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/03/18	21:00	GlobeNewswire Inc.	Elicio Therapeutics Announces $6.0 Million Private Placement Financing	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/02/05	22:30	GlobeNewswire Inc.	Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/01/25	23:00	GlobeNewswire Inc.	Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/01/17	22:30	GlobeNewswire Inc.	Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/01/16	22:30	GlobeNewswire Inc.	Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/01/11	22:30	GlobeNewswire Inc.	Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study	NASDAQ:ELTX	Elicio Therapeutics Inc
2024/01/09	20:00	GlobeNewswire Inc.	Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002	NASDAQ:ELTX	Elicio Therapeutics Inc
2023/12/22	23:00	GlobeNewswire Inc.	Elicio Therapeutics Announces $7.0 Million Private Placement Financing	NASDAQ:ELTX	Elicio Therapeutics Inc
2023/12/04	22:00	GlobeNewswire Inc.	Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference	NASDAQ:ELTX	Elicio Therapeutics Inc
2023/11/10	06:30	GlobeNewswire Inc.	Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates	NASDAQ:ELTX	Elicio Therapeutics Inc
2023/11/04	05:30	GlobeNewswire Inc.	Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting	NASDAQ:ELTX	Elicio Therapeutics Inc
2023/10/11	21:00	GlobeNewswire Inc.	Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting	NASDAQ:ELTX	Elicio Therapeutics Inc
2023/09/28	06:30	GlobeNewswire Inc.	Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer	NASDAQ:ELTX	Elicio Therapeutics Inc
2023/09/07	21:00	GlobeNewswire Inc.	Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines	NASDAQ:ELTX	Elicio Therapeutics Inc
2023/09/06	21:00	GlobeNewswire Inc.	Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:ELTX	Elicio Therapeutics Inc
2023/09/05	21:00	GlobeNewswire Inc.	Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer	NASDAQ:ELTX	Elicio Therapeutics Inc